Business Wire

AI-Powered Creator Monetisation Platform, Fanvue, Hits $100m Run Rate and Raises $22m Series A Investment - as Leading Global Creators Rush to Join the Platform

19.1.2026 01:01:00 CET | Business Wire | Press Release

Share

Fanvue, the AI-powered creator monetisation platform with a $100m-plus run rate, has announced a $22m Series A investment round.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112458975/en/

Joel Morris, Will Monange and Harry Fitzgerald (left to right)

Fanvue has bet big on AI-powered tools changing the face of an industry estimated to be worth over $500B by 2030. The platform, which recently crossed $100m annualised revenue, has over 17 million monthly active users, and is home to 250,000 creators who are using Fanvue’s pioneering AI tools to scale their businesses and earn.

Instead of competing with legacy platforms, Fanvue is defining a new category, the Creator AI Economy. Fanvue’s belief is that the next generation of creators will accelerate their earnings through utilising technology. And it’s happening in real time. According to Fanvue, just over 93% of creators on the platform used at least one of the platform’s proprietary AI tools, which include Analytics, Voice and Content.

Investors share Fanvue’s vision for the AI-powered creator economy. The Series A was led by Inner Circle (www.iccap.co), backed by 50+ exited founders, financiers and cultural icons across sport and entertainment, whose portfolio also includes Revolut, Anthropic and xAI. Other notable backers include Moonbug founder René Rechtman, who oversaw its multi-billion-dollar exit, the founders of UK unicorn Marshmallow, and GPs from leading European venture firms.

James Cox, Co-Founder of Inner Circle, commented:

“AI is redefining the creator economy. Fanvue isn’t reacting to that shift; they are pioneering it. Joel, Will, Harry and the team are building the category-defining platform, enabling creators globally to monetise their audiences at scale. We’re proud to be their partner, opening up our community’s access, influence and distribution as they scale.”

Underpinning Fanvue’s AI-powered solutions for the Creator AI Economy are three fundamental values: Fan Connection, Creator Freedom, and Business Ownership. These values stem from the experiences of Co-Founder and former YouTuber, Joel Morris, who identified pain points as a creator that needed fixing - launching Fanvue in 2022 alongside fellow Co-Founders, Will Monange, and Harry Fitzgerald.

The business reported a 450% revenue increase YoY, while their global staff headcount has increased from 42 to 115 in 12 months. The leadership team and the core of the business operate from its London hub in Canary Wharf. Fanvue was recognised as the Fastest Growing Company in Europe at the recent International Business Awards (Stevies).

Fanvue has just announced the signing of Alisha Lehmann, the Swiss pro-footballer, who has become one of the world’s leading content creators, with over 16 million followers on Instagram.

It’s a “huge statement and a stamp of approval for Fanvue’s vision”, says Co-Founder and CEO, Will Monange, who added:

“Announcing two major milestones for the business, the Series A and Alisha, in the same week, reinforces our vision that AI will enable the next generation of athletes and creators to build businesses and create new revenue streams on direct-to-fan monetisation platforms like Fanvue.”

Over 20,000 new creators joined Fanvue last month, with a series of major mainstream creators expected to be announced at the start of 2026.

Fitzgerald, Co-Founder and COO, commented:

“Thanks to AI, creators on Fanvue will be able to scale products, content, and connections in ways that weren’t possible before. The technology will shift creators' ability to directly monetise their fanbases, when traditionally they've had to rely on advertising. We’re building a product that will revolutionise the creator economy.”

The $22m Series A investment will be used to accelerate Fanvue’s global expansion, invest in world-class talent, and leverage AI capabilities to build a product and team that Co-Founder and CEO, Joel Morris, believes will “change the face of the Creator Economy for good”.

Morris added:

“We’ve quietly been building a world-class team from our London base, hiring from Amazon and TikTok in key leadership positions to deliver on our vision to transform how creators monetise content on a global scale. This fundraise enables us to accelerate those plans. We’re just getting started.”

-Ends-

Notes to Editors:

About Fanvue

Fanvue is the fastest-growing subscription platform in the creator economy, with 17 million monthly active users and over 250,000 creators.

Business Awards

  • Fastest Growing Company in Europe at the recent International Business Awards (Stevies)
  • Sunday Times Best Places to Work 2025, due to its innovative culture and commitment to building a world-class environment for talent

View source version on businesswire.com: https://www.businesswire.com/news/home/20260112458975/en/

Contacts

UK-based reporters can get in touch with gabriella@ideafarmer.co.uk or
scarlett@ideafarmer.co.uk, and US-based reporters can email
mereditheklein@gmail.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye